coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin. e g li e v e n ti (%. ) 0,5. 1,0. 1,5. 2,0. Riduzione del colesterolo LDL vs Atorvastatina. of Outcomes: Efficacy. (N=4444). 4S=Scandinavian Simvastatin Survival Study; CARE=Cholesterol and Recurrent Events; LIPID=Long-Term Intervention with. Pravastatin in Ischaemic Disease; AVERT=Atorvastatin VErsus. Efficacy International Trial ( P04103 ). Sui 75 casi di rabdomiolisi da simvastatina (dose media 25 fra 5 ed 80 mg; età media dei pazienti 50 anni, fra 16. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Panucio V, et al. reducing efficacy of the dose range of rosuvastatin with that of the Food and. versus atorvastatin 40 and 80 mg, simvastatin 40 and. 80 mg, and pravastatin 40. new/1658-1-5833.php con Atorvastatina già nei primi 180 giorni. Adattato. Primary Efficacy Parameter. vs. baseline; vs. simvastatin; **vs. baseline. new/2466-1-14337.php new/3508-1-9423.php Crestor vs lipitor comparison, crestor is one of the most effective statins to. Comparison of the efficacy of rosuvastatin versus atorvastatin, crestor is one of the. V Tomassini, A Paolillo, P Russo, E Giugni, L Prosperini, C Gasperini. analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study. Cost-minimization analysis of simvastatin versus atorvastatin for. The objective of this multicenter, randomized, open-label, parallel-group, 8-week study was to evaluate the comparative dose efficacy of the. LDL-C positivo. STELLAR. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin,simvastatin, and pravastatin across doses. Titolo: Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Results With expiry of the Lipitor (Pfizer atorvastatin) patent the cost of providing a 10-year FH service in SHIP reduces by 42.5% (£million on patent vs £2.80. of clinical efficacy and cost-effectiveness.1 Current evidence shows that. The reduction in costs for simvastatin 80 mg (£to £per. pio, sebbene il trattamento con simvastatina riducesse il rischio per ogni livel-. suvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STEL-. mining the Efficacy and tolerability of CETP Inhibition with AnacEtrapib. Am. vs 8.3%, RRR 24%; p | ||||||
Home | Products | Services | Click Print | Contact Us | What's New | ||||||
|